Ballwin, MO, United States of America

Lu Hwang-Fun

This inventor holds 1 USPTO granted patent. Top assignee: G.d. Searle & Company. Active years: 2003.


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lu Hwang-Fun: Innovator in Anti-Inflammatory Pharmaceutical Agents

Introduction

Lu Hwang-Fun is a notable inventor based in Ballwin, MO (US). He has made significant contributions to the field of anti-inflammatory pharmaceutical agents. His work focuses on developing compounds that can effectively treat disorders mediated by cyclooxygenase-2 or 5-lipoxygenase.

Latest Patents

Lu Hwang-Fun holds a patent for "Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors." This invention is crucial in the development of new treatments for inflammation-related disorders. The patent highlights his innovative approach to creating compounds and compositions that target specific inflammatory pathways.

Career Highlights

Throughout his career, Lu Hwang-Fun has been associated with G.D. Searle & Company, where he has contributed to various research initiatives. His expertise in pharmaceutical development has positioned him as a key figure in the industry. He has successfully navigated the complexities of drug development, leading to advancements in therapeutic options for patients.

Collaborations

Lu has worked alongside esteemed colleagues such as John Jeffrey Talley and James A. Sikorski. Their collaborative efforts have further enhanced the research and development of innovative pharmaceutical solutions.

Conclusion

Lu Hwang-Fun's contributions to the field of anti-inflammatory agents exemplify the impact of innovative thinking in pharmaceutical research. His patent and collaborative work continue to influence the development of effective treatments for inflammatory disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…